Company: DMAC
Filing Date: 2025-12-18
Form Type: 8-K
Source: 0001437749-25-038211
Chunk: 2

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-12-18
Form: 8-K
Item: Item 8.01
Chunk 2
---
199; DiaMedica’s ability to conduct successful clinical testing of DM199 and within its anticipated parameters, site activations, enrollment numbers, costs and timeframes; the perceived benefits of DM199 over existing treatment options; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain shortages on DiaMedica’s business and clinical trials, including its ability to meet its site activation and enrollment goals; DiaMedica’s reliance on collaboration with third parties to conduct clinical trials; DiaMedica’s ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke and the risks identified under the heading “ Risk Factors” in DiaMedica’s annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U. S. Securities and Exchange Commission (SEC) and subsequent SEC reports. The forward-looking information contained in this report represents the expectations of DiaMedica as of the date of this report and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Item 9.01Financial Statements and Exhibits.